Fig. 7: Targeting SNHG3 c.1746 A > I overcomes DTX resistance in NSCLC. | Communications Biology

Fig. 7: Targeting SNHG3 c.1746 A > I overcomes DTX resistance in NSCLC.

From: A-to-I edited SNHG3 promotes non-small cell lung cancer metastasis by promoting fatty acid oxidation and resisting ferroptosis

Fig. 7

a Drug sensitivity analysis identifies six drugs as candidates correlated with SNHG3 expression (FDR < 10−6). b Increased DTX and methotrexate resistance in SNHG3ED cells (n = 3-5, two-way ANOVA). c Dose-dependent increase in c.1746 A > I editing in A549DR cells (n = 3, one-way ANOVA with Dunnett multiple comparisons test). d Upregulated ADAR1 protein levels in A549DR cells (n = 4, one-way ANOVA). e Therapeutic strategy using LNA-ASOC2 in A549DR cells, xenografts and PDOs. f LNA-ASOC2 restores DTX sensitivity in A549DR cells (n = 4, two-way ANOVA with Tukey’s test). g Bioluminescence imaging of A549DR xenografts post-treatment (n = 5; Scale bar = 1 cm). h Tumor volume reduction with LNA-ASOC2 + DTX combination therapy (n = 5, two-way ANOVA with Tukey’s test). i Representative images of excised xenograft tumors. j LNA-ASOC2 enhances DTX efficacy in patient-derived organoids (n = 6, one-way ANOVA with Tukey’s test). Data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. N indicates biological replicates.

Back to article page